Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of EDG-5506 in Becker muscular dystrophy
2023-506231-15-00Phase 2Authorised
- Sponsor
- Edgewise Therapeutics
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of sevasemten in Becker muscular dystrophy (BMD), sponsored by Edgewise Therapeutics. Primary endpoint: Incidence, frequency, and severity of TEAEs and SAEs. Planned start Feb 2024; status: authorised.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on 2023-506231-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506231-15-00.